Dr Reddys Laboratories Ltd Share Price

Dr. Anji Reddy founded Dr. Reddy's Laboratories in 1984 in Hyderabad, India, with an initial capital of ₹25 lakh. After starting to produce Active Pharmaceutical Ingredients and Intermediates (APIs), the business introduced methyldopa to the global market. The USFDA originally approved the company's Ibuprofen API in 1987. In 1991, the company began producing Omeprazole, a popular drug. In 1993, Dr. Reddy's Research Foundation focused on drug discovery for cancer and diabetes. In 1998, the company started biologics to offer affordable medicine to Indian consumers. In 2003, Ibuprofen was launched under their label in the US. In 2019, the company entered the nutrition segment in India with Celevida. Keep track of Dr. Reddy’s Laboratories share price with BlinkX. Dr Reddy share price history in India is characterised by oscillations caused by a variety of factors, including changes in the global energy environment, regulatory measures, and market demand.

Key Personnel of Dr. Reddy’s Laboratories

Erez Israeli, CEO

Erez Israeli, with an MBA from Bar-Ilan University and over 30 years of experience, became CEO of Dr. Reddy's Laboratories in July 2019. He previously held positions at Enzymotec and Teva Pharmaceuticals, specialising in sales and marketing.

G V Prasad, Co-chairman and MD

Mr. Prasad, who joined Dr. Reddy in 1990, has overseen the company's growth from a small domestic operation to a major global pharma brand, focusing on research, innovation, and corporate ethics.

Business Segment Dr. Reddy's Laboratories

Dr. Reddy's Global Presence and Business Overview

Generics, biosimilars, differentiated formulations, Active Pharmaceutical Ingredients (APIs), bespoke pharmaceutical services, and more are all provided by Dr. Reddy's Laboratories.
Focuses on gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Europe, Russia, India, and the United States are important markets.
Primary businesses include pharmaceutical services and active ingredients production, global generic drug production, and proprietary products.
As of March 2023, the company had 40 subsidiaries abroad and 9 in India.

BlinkX allows you to follow the Dr Reddy share price on the NSE and BSE on a daily basis.

Financial Highlights of Dr. Reddy’s Laboratories

The company's sales revenue increased by more than 100% from March 2013 to March 2023.
On the other hand, the company's net earnings increased by around 200% in the same period.
The net cash flows of the corporation have fluctuated during the past several years. After being negative for a few years, it increased to ₹1,286 crore in FY 2021; however, it dropped to ₹3 in FY 2022 and even lower to -₹907 crore in FY 2023.

Dr Reddys Laboratories Ltd

DRREDDY Share Price